At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial (TAYSIDE Trial)
In Brief
A Phase 4 clinical trial evaluating Metformin and Matched Placebo (Capsules) for Congestive Heart Failure and Insulin Resistance. Completed, enrolled 62 participants across 1 site.
Detailed Summary
Will metformin improve exercise capacity in chronic heart failure patients who has insulin resistance (pre-diabetic- means before they become diabetic)?
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure, Insulin Resistance
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartAug 2007
Primary CompletionApr 2009
TodayJul 2026
First PostedMay 16, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.1 years ago
Interventions
Metformindrug
Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
Matched Placebo (Capsules)drug
Similar dosing regime as active comparator